// App-Quantinova.ai

: LOSS OF HEPATITIS B CORE ANTIBODIES EARLY IN ALLO-HSCT MAY HELP PREDICT PROGNOSIS IN PATIENTS WITH HBSAG-NEGATIVE/ANTI-HBC-POSITIVE: A SINGLE-CENTER OBSERVATIONAL STUDY OF 141 PATIENTS

Researchers

Presenter

  • Jinhua Ren

Principal Investigators

  • Tingting Xiao

  • Yingxi Weng

  • Yu Zhang

  • Xiaofeng Luo

  • Zhihong Zheng

  • Zhizhe Chen

  • Jianda Hu

  • Ting Yang

Medical Centers

  • Fujian Medical University Union Hospital, Fuzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

  • Autoimmune (AI)

  • Gastroenterology (GU)

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Drug-induced liver injury

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Aplastic anemia

  • Hepatitis B

  • Lymphomas

  • Anemia

Biomarkers

  • Serum hepatitis B virus DNA

Drug/Treatment

  • Entecavir

  • Allopurinol

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved